SeaStar Medical Holding Corporation
NASDAQ · us_market
No AI insight generated yet for this ticker.
SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -0.82 | -0.90 | -9.09% |
| 2026-03-25 | -1.01 | -0.80 | +21.18% |
| 2025-11-13 | -1.50 | -1.30 | +13.33% |
| 2025-08-13 | -4.30 | -1.80 | +58.14% |
| 2025-05-14 | -5.20 | -4.40 | +15.38% |
| 2025-03-27 | -8.90 | -9.00 | -1.12% |
| 2024-11-13 | -11.30 | -11.00 | +2.65% |
| 2024-08-13 | -14.10 | -10.30 | +26.95% |
| 2024-05-14 | -37.50 | -47.50 | -26.67% |
| 2024-04-16 | -32.50 | -47.50 | -46.15% |
| 2023-11-14 | -62.50 | -92.50 | -48.00% |
| 2023-08-14 | -62.50 | -62.50 | — |
| 2023-05-15 | -50.00 | -100.00 | -100.00% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ICU | -15.10% | +44.92% | +54.58% | -68.82% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -18.07% | +49.56% | +58.03% | -81.51% |